health

Triangle precision medicine, drug research firm Metabolon lands $25M in new capital

MORRISVILLE – Metabolon is preparing to further advance its global mission in precision medicine and drug research through study of the metabolome with $25 million in new equity funding.

The metabolome refers to the complete set of small molecule chemicals found in a biological sample.

Metabolon recently signed a testing agreement with Mayo Clinic.

Metabolon studies more than just genetics as part of its research effort, deciphering “thousands of separate chemical signals from genetic and non-genetic factors to discover biomarkers and reveal biological pathways,” the company says.

Biotech Deep Dive: Inside Metabolon’s Biomarker Testing Agreement with Mayo Clinic

“Proceeds will be used for general corporate purposes, enabling Metabolon to further accelerate commercialization activities and continue to advance its well-defined R&D roadmap,” the private company said in the funding announcement.

“Metabolon is experiencing significant growth and we are excited to continue building our talented team and scaling our capabilities to meet increasing demand,” said Rohan Hastie, CEO of Metabolon. “Metabolomics is an essential part of the life science ecosystem. All omics approaches – genomics, proteomics, metabolomics – are highly complementary. You cannot fully understand biology, and more specifically systems biology, by looking solely at DNA, proteins or metabolites. As the life sciences evolve towards a more advanced multi-omics approach, Metabolon is fast becoming an industry standard and a critical step towards true precision medicine.”

In November 2021, Metabolon unveiled a new platform for study of the metabolome.

‘Demystifies’ the gut: RTP biotech Metabolon unveils new metabolome platform

And the company had a successful 2022, according to Chief Financial Officer Gerry Haines.

“This funding comes on the heels of record sales and margins in 2022 and comes primarily from new investors, with additional participation from existing investors,” Haines said in the funding announcement. “The infusion of capital enables us to continue accelerating our already robust growth and execution as we bring market-leading metabolomics and associated deep phenotyping capabilities to a fast-growing market”

Previous post
Erkältung, Grippe, Bronchitis: Krankenkasse meldet Rekordwert bei Fehltagen in 2022
Next post
Moyes proved right over Danjuma as star turns back on Everton for Spurs